ASCO Plenary Feb 2024 - ASCO Plenary Series: February 2024
Feb 06 - Feb 06, 2024 | AlexandriaVAUS
LARVOL is not affiliated with ASCO Plenary Series: February 2024 and all trademarks, logos, and brand names are property of their respective owners
Condition
Product
MOA
Trial Name/ID
Showing 2 titles linked to Trials
Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM).
Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study.